Lupin's partner Concord gets USFDA nod to market generic Myfortic tablet

Pharma major Lupin on Thursday said its alliance partner Concord Biotech has received approval from the US health regulator for generic immunosuppressive Mycophenolic acid delayed-release tablets.

The approval from the United States Food and Drug Administration (USFDA) is to market Mycophenolic acid delayed-release tablets USP in the strengths of 180 mg and 360 mg, Lupin said in a statement.

The product is a generic version of Novartis Pharmaceuticals Corporation's Myfortic delayed-release tablets in the same strengths, it added.

According to IQVIA MAT September 2019 data, Mycophenolic acid delayed-release tablets USP, 180 mg and 360 mg had annual sales of around USD 174 million in the US market, Lupin said.

The tablets are indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant, it added.

Myfortic is to be used in combination with cyclosporine and corticosteroids, Lupin said.

Shares of Lupin Ltd closed at Rs 770.70 per scrip on BSE, up 0.60 per cent from its previous close.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel